/

Società

Ve

Non verificato

Veradermics

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteSanità

4 comunicati stampa

Guarda tutti i comunicati

11/12/2025

Veradermics Completes Enrollment in its Phase 2/3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss, Advancing Development of the Potential First-Ever Extended-Release Oral Minoxidil

Fonte

Emittente

1.00

0

18/11/2025

Industria

Biotecnologia

Sanità

Salute

Farmaceutica

Medicina - Varie

Veradermics Advances VDPHL01 in Phase 2/3 Clinical Trial for Female Pattern Hair Loss, Marking a Milestone in the Development of the Potential First-Ever Oral Prescription Treatment for Women

Fonte

Emittente

1.00

0

16/10/2025

Veradermics Announces Oversubscribed $150 Million Series C Financing to Advance VDPHL01 Through Multiple Phase 3 Trials as Potentially the First Non-Hormonal Oral Therapeutic for Hair Regrowth in Women and Men

Fonte

Emittente

1.00

0

11/12/2024

Mercato del lavoro

Salute

Sanità

Medicina - Varie

Farmaceutica

Biotecnologia

Veradermics Raises $75 Million in Series B Financing and Initiates Phase 2/3 Trial for Hair Loss

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0